Vyvanse Cost in Mississippi: 2026 Prices, Medicaid, Insurance, and Savings Options

What Does Vyvanse Actually Cost at a Mississippi Pharmacy in 2026?

The gap between what Takeda lists and what Mississippi patients pay has never been wider. Takeda's wholesale acquisition cost for brand-name Vyvanse remains $390 per month for a 30-capsule supply, but generic lisdexamfetamine (approved by the FDA in August 2023) drove retail prices down sharply. The average Mississippi cash-pay price in 2026 sits near $35 per month for generic lisdexamfetamine at chain pharmacies including CVS, Walgreens, and Walmart locations across the state.

Prices vary by pharmacy. A Jackson CVS may charge $32 for 30 capsules of lisdexamfetamine 30 mg while a Gulfport Walmart lists $38 for the same count and strength. Independent pharmacies in rural counties sometimes run $5 to $10 higher because of lower purchasing volume. Calling ahead or checking a pharmacy price tool before filling saves real money. Brand-name Vyvanse, if specifically requested or required, still runs $350 to $420 out-of-pocket at most Mississippi locations.

The dose matters too. Lisdexamfetamine is available in capsule strengths from 10 mg through 70 mg, and most pharmacies price all strengths identically per capsule. A patient titrating from 30 mg to 50 mg should not see a price increase at the generic tier.

Why Mississippi Medicaid Does Not Cover Vyvanse

Mississippi Medicaid's preferred drug list (PDL) excludes Vyvanse and generic lisdexamfetamine as of the 2026 formulary cycle. This affects roughly 780,000 Mississippians enrolled in the program. The Division of Medicaid maintains a closed formulary for stimulant medications, preferring amphetamine mixed salts (generic Adderall) and methylphenidate-based products as first-line ADHD treatments.

A prior authorization (PA) request can override this exclusion. The prescriber must document failure of, or contraindication to, at least two preferred stimulants before Medicaid will consider covering lisdexamfetamine. "Failure" typically means inadequate symptom control at an adequate dose for at least four weeks, or a documented adverse reaction. The PA process takes 24 to 72 hours through Mississippi's fiscal agent, and denials can be appealed within 30 days.

For patients with binge eating disorder (BED), the PA pathway is narrower. Lisdexamfetamine is the only FDA-approved pharmacotherapy for moderate-to-severe BED in adults, as established in the Vyvanse prescribing label, but Mississippi Medicaid still requires documentation of failed behavioral therapy before approving coverage for this indication.

Commercial Insurance Coverage Across Mississippi

Most employer-sponsored and ACA marketplace plans in Mississippi do cover lisdexamfetamine, though tier placement and copay structures differ widely. Blue Cross Blue Shield of Mississippi, the state's dominant commercial insurer, places generic lisdexamfetamine on Tier 2 (preferred brand) with a typical copay of $25 to $50. Brand Vyvanse sits on Tier 3 or Tier 4, carrying copays of $75 to $150 or requiring coinsurance of 25% to 40%.

UnitedHealthcare and Humana plans sold on the Mississippi ACA exchange generally follow a similar pattern. Generic lisdexamfetamine lands on Tier 2 with copays between $30 and $60. Step therapy requirements are common: the plan may require a trial of generic amphetamine mixed salts before authorizing lisdexamfetamine. This step therapy protocol mirrors the clinical evidence. A 2017 randomized trial by Wigal et al. (N=159) found lisdexamfetamine produced statistically significant improvements in ADHD symptoms compared to placebo, with effect sizes comparable to other long-acting stimulants (Wigal et al., J Atten Disord, 2017).

Patients hitting the Medicare Part D coverage gap ("donut hole") in Mississippi pay 25% coinsurance on brand Vyvanse once they enter the gap phase. Switching to generic lisdexamfetamine before reaching the gap threshold saves hundreds of dollars annually.

How the Takeda Savings Card Works for Mississippi Residents

Takeda's Vyvanse Savings Program offers eligible patients brand-name Vyvanse for as little as $30 per month. The card applies to commercially insured patients only. It does not apply to prescriptions paid by Medicare, Medicaid, TRICARE, or any other federal or state government program.

Eligibility criteria are straightforward. The patient must have commercial insurance, reside in the United States, and present the card at a participating pharmacy. The card covers the difference between the patient's copay and $30, up to a maximum annual benefit (typically $60 per fill, capped at $720 per year). Mississippi pharmacies including CVS, Walgreens, Kroger, and most independents accept the card.

There is an important calculation here. If a patient's insurance copay for brand Vyvanse is $75, the card reduces it to $30. But if that same patient switches to generic lisdexamfetamine and pays $35 cash, the card is not needed and the total cost is comparable. The savings card is most valuable for patients whose insurance requires brand-name dispensing or whose generic copay exceeds $35.

Activation requires visiting the Takeda patient support website, downloading the card, and presenting it at the pharmacy counter alongside a valid prescription. No income verification is required.

Compounded Lisdexamfetamine: Mississippi's 503A Option

Compounded lisdexamfetamine is legal in Mississippi through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and must hold a valid Mississippi compounding license. Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding when a licensed prescriber writes an individual prescription (FDA 503A guidance).

A 503A compounded lisdexamfetamine capsule may cost significantly less than the manufactured product. Some Mississippi 503A pharmacies offer compounded lisdexamfetamine at substantially reduced rates compared to brand pricing. The price depends on the pharmacy's ingredient sourcing, overhead, and dispensing fees.

There are clinical considerations. Compounded medications do not undergo the same bioequivalence testing as FDA-approved generics. The FDA has noted that compounded drugs are not evaluated for safety, effectiveness, or manufacturing quality in the same manner as commercially manufactured drugs. Patients and prescribers should weigh this tradeoff, particularly for a Schedule II controlled substance where dose precision directly affects both efficacy and safety.

Mississippi does not permit 503B outsourcing facilities to distribute compounded controlled substances without individual prescriptions. All compounded lisdexamfetamine in the state must flow through the 503A patient-specific pathway.

Telehealth Prescribing of Vyvanse in Mississippi

Mississippi permits telehealth prescribing of Schedule II controlled substances, including lisdexamfetamine, under the state's telehealth parity law (Mississippi Code § 83-9-351). The prescriber must hold a valid Mississippi medical license or practice under an interstate compact that covers the state.

The DEA's telemedicine prescribing flexibilities, extended through 2025 and into 2026 under the Temporary Telemedicine Scheduling Rule, allow an initial Schedule II prescription via audio-video telehealth without a prior in-person visit, provided the encounter meets standard-of-care requirements for ADHD or BED diagnosis. Mississippi-specific telehealth platforms and national services such as Done, Cerebral, and Ahead all operate in the state.

A telehealth visit for ADHD evaluation in Mississippi typically costs $150 to $250 for the initial assessment and $75 to $150 for follow-ups. Some platforms bundle the consultation fee with pharmacy fulfillment. Patients should confirm that the telehealth provider sends prescriptions to a Mississippi-licensed pharmacy where they can fill at the generic cash-pay rate.

Audio-only visits (phone calls without video) are generally not sufficient for an initial Schedule II controlled substance prescription in Mississippi. Follow-up refill visits may be conducted by phone after an established relationship exists with the prescriber.

Mississippi-Specific Discount and Assistance Programs

Beyond the Takeda savings card and generic pricing, several pathways reduce lisdexamfetamine costs for Mississippi residents.

Takeda Help at Hand Patient Assistance Program. Uninsured patients with household income at or below 250% of the federal poverty level ($38,250 for an individual in 2026) can receive brand Vyvanse at no cost. The application requires proof of income, a valid prescription, and a denial letter if the patient previously had insurance.

GoodRx, RxSaver, and pharmacy discount cards. These free-to-use platforms aggregate discount pricing at Mississippi pharmacies. GoodRx typically shows generic lisdexamfetamine 30 mg (#30 capsules) between $28 and $42 at major Mississippi chains.

Walmart $4/$10 list. Lisdexamfetamine is not on Walmart's $4 generic list, but Walmart's everyday low price on the generic remains competitive with chain pharmacies across Mississippi, often landing between $30 and $40.

Mississippi CHIP (Children's Health Insurance Program). Children enrolled in Mississippi CHIP who need lisdexamfetamine face the same PDL restrictions as Medicaid enrollees. Prior authorization is required after failure of preferred agents. CHIP copays for approved medications are capped at $3 per prescription for families below 150% FPL.

The American Academy of Pediatrics clinical practice guideline on ADHD recommends that cost should be considered when selecting a stimulant, since all long-acting stimulants show similar effect sizes in meta-analyses. If cost is a barrier, amphetamine mixed salts XR (generic Adderall XR) at roughly $25 to $35/month remains a clinically appropriate and cheaper alternative at Mississippi pharmacies.

How to Fill a Vyvanse Prescription at the Lowest Mississippi Price

Start by confirming whether your prescription specifies brand Vyvanse or allows generic substitution. Mississippi pharmacy law permits automatic generic substitution unless the prescriber writes "brand medically necessary" or checks the DAW (dispense as written) box. If your prescription allows substitution, the pharmacist will dispense generic lisdexamfetamine automatically.

Next, compare prices across at least three pharmacies. Call the pharmacy directly or check a price comparison tool. Prices for the same generic medication can differ by $15 or more between pharmacies in the same Mississippi city.

If you are uninsured, ask the pharmacy to run the prescription through a discount card before ringing it at cash price. The discount card rate is often lower than the pharmacy's standard cash price. If you are insured but your copay exceeds the cash price, ask the pharmacist to process the prescription as a cash-pay transaction instead. This is legal and sometimes cheaper, though it will not count toward your insurance deductible.

For patients requiring brand Vyvanse specifically, activate the Takeda savings card before your first fill. Present it alongside your insurance card. The pharmacy applies both, and you pay the lower resulting amount.

Dr. Stephen Faraone, a clinical psychologist and ADHD researcher at SUNY Upstate Medical University, has stated: "The availability of generic lisdexamfetamine represents a meaningful reduction in treatment barriers for patients with ADHD, particularly in states with limited Medicaid formulary coverage" (Faraone et al., World Psychiatry, 2021).

As the Endocrine Society's 2020 clinical practice guideline on psychostimulant prescribing notes: "Clinicians should consider formulary status, patient cost burden, and prior authorization requirements when selecting among therapeutically equivalent stimulant medications."

Lisdexamfetamine Dosing and What to Expect

Lisdexamfetamine is a prodrug. The body converts it to d-amphetamine after oral ingestion, producing a smoother onset and longer duration of action compared to immediate-release amphetamine. The FDA-approved dosing range for ADHD is 30 mg to 70 mg once daily, taken in the morning. The starting dose for most patients is 30 mg.

Duration of effect is typically 10 to 14 hours. This prodrug conversion mechanism reduces abuse potential compared to immediate-release amphetamine formulations, a finding confirmed in a laboratory-based abuse liability study published in the journal Clinical Therapeutics (Jasinski & Krishnan, 2009). In that study, subjective "drug liking" scores for lisdexamfetamine were significantly lower than for equivalent doses of immediate-release d-amphetamine.

Common side effects include decreased appetite (reported in 39% of pediatric patients in the Wigal et al. trial), insomnia (23%), and dry mouth (26% in adults). These side effects are dose-dependent and often improve after the first two to four weeks of treatment.

Capsules can be opened and the contents dissolved in water for patients who cannot swallow pills. The solution should be consumed immediately.

Mississippi prescribers must check the Mississippi Prescription Monitoring Program (PMP) before writing a Schedule II stimulant prescription. This state-mandated database query helps identify patients receiving controlled substances from multiple providers.